THE SENATE

THE THIRTIETH LEGISLATURE

REGULAR SESSION OF 2020

 

COMMITTEE ON COMMERCE, CONSUMER PROTECTION, AND HEALTH

Senator Rosalyn H. Baker, Chair

Senator Stanley Chang, Vice Chair

 

NOTICE OF DECISION MAKING

 

 

DATE:

Tuesday, February 11, 2020

TIME:

10:15 AM

PLACE:

Conference Room 229

State Capitol

415 South Beretania Street

 

A G E N D A

 

The following measures were previously heard on February 7, 2020. Due to a scheduling conflict, the decision making for these measures will be held at 10:15am instead of the times announced by the Chair at the hearing:

 

SB 3045

      Status & Testimony

RELATING TO PRESCRIPTION DRUG RATE SETTING.

Establishes a prescription affordability commission within the Department of Commerce and Consumer Affairs to review prescription drug costs and establish levels of reimbursement.  Appropriates moneys.

 

CPH, WAM

SB 2024

      Status & Testimony

RELATING TO MEDICAL CANNABIS.

Allows for a process to remediate any batch of cannabis that fails laboratory testing standards so long as any final product passes all such laboratory standards.  Authorizes licensed retail dispensaries to sell edible cannabis products, under certain conditions, and circulate, sponsor, and promote educational and scientific information and events related to cannabis.

 

CPH, JDC

SB 2280

      Status & Testimony

RELATING TO PHARMACY BENEFIT MANAGERS.

Prohibits pharmacy benefit managers from engaging in self-serving business practices.  Replaces registration requirement with license requirement for pharmacy benefit managers.  Increases pharmacy benefit manager reporting requirements to the insurance commissioner.  Increases application and renewal fees and penalties for failure to renew a license.

 

CPH, JDC

SB 2276

      Status & Testimony

RELATING TO PRESCRIPTION DRUGS.

Requires drug manufacturers to notify prescription drug benefit plans and pharmacy benefit managers if a proposed increase in the wholesale price of certain drugs would result in a sixteen per cent or more price increase over a two year period.  Requires the drug manufacturer to identify and report to the insurance commissioner information on certain drugs whose wholesale acquisition cost increases by a certain amount during a specified time frame.  Imposes fines.

 

CPH, JDC

SB 2278

      Status & Testimony

RELATING TO HEALTH INSURANCE.

Establishes disclosure and consent requirements for nonparticipating health care providers.  Prohibits nonparticipating health care providers from balance billing patients in specific circumstances.  Establishes rate calculation requirements for reimbursement of nonparticipating providers.

 

CPH, JDC

 

Decision making meeting only, no public testimony will be accepted.

 

FOR AMENDED NOTICES:  Measures that have been deleted are stricken through and measures that have been added are underscored.  If a measure is both underscored and stricken through, that measure has been deleted from the agenda.

 

If you require auxiliary aids or services to participate in the public hearing process (i.e. ASL or foreign language interpreter, or wheelchair accessibility), please contact the committee clerk at least 24 hours prior to the hearing so that arrangements can be made.

 

FOR FURTHER INFORMATION, PLEASE CALL THE COMMITTEE CLERK AT (808)586-6070.

 

 

 

 

_____________________________________

Senator Rosalyn H. Baker

Chair